Abstract
Heart failure (HF) is a clinical syndrome of diverse etiologies and can be associated with preserved, reduced, or mid-range ejection fraction (EF). In the community, heart failure with preserved ejection fraction (HFpEF) is emerging as the most common form of HF. There remains considerable uncertainty regarding its pathogenesis, diagnosis, and optimal therapeutic approach. Hypotheses have been advanced to explain the underlying pathophysiology responsible for HFpEF, but to date, no specific therapy based on these hypotheses has been proven to improve outcomes in HFpEF. We provide a clinically focused review of the epidemiology, clinical presentation, diagnostic approach, pathophysiology, and treatment of HFpEF.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 65-79 |
| Number of pages | 15 |
| Journal | Annual Review of Medicine |
| Volume | 69 |
| DOIs | |
| State | Published - Jan 29 2018 |
Keywords
- Cardiomyopathy
- Diastolic heart failure
- Hypertension
- Pulmonary hypertension
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
Fingerprint
Dive into the research topics of 'Heart Failure with Preserved Ejection Fraction'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS